SR ONE CAPITAL MANAGEMENT, LP

Est. AUM

$915.4M

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	Arcellx, Inc.	Common Stock	$269.4M	2346630	29.43%	SOLE
2	Veradermics, Inc.	Common Stock	$151.7M	2401868	16.57%	SOLE
3	Zenas BioPharma, Inc	Common Stock	$98.5M	5037854	10.76%	SOLE
4	CRISPR Therapeutics AG	Common Shares	$97.0M	2038763	10.59%	SOLE
5	Design Therapeutics, Inc.	Common Stock	$69.4M	6526476	7.59%	SOLE
6	ORIC Pharmaceuticals, Inc.	Common Stock	$58.5M	4514929	6.39%	SOLE
7	Alumis Inc.	Common Stock	$43.2M	1959896	4.72%	SOLE
8	Mineralys Therapeutics Inc.	Common Stock	$42.4M	1563966	4.63%	SOLE
9	ARS Pharmaceuticals, Inc.	Common Stock	$32.2M	4012903	3.52%	SOLE
10	Oruka Therapeutics, Inc	Common Stock	$21.1M	430330	2.31%	SOLE
11	Oculis Holding AG	Ordinary Shares	$17.0M	641022	1.86%	SOLE
12	Nkarta, Inc.	Common Stock	$7.0M	3333333	0.77%	SOLE
13	enGene Holdings Inc.	Common Shares	$5.1M	747750	0.56%	SOLE
14	Ultragenyx Pharmaceutical Inc.	Common Stock	$2.9M	137753	0.32%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.